Tags : Biogen

Weekly Snapshot

PharmaShots Weekly Snapshots (October 04 – 08, 2021)

AbbVie’s Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis Published: Oct 8, 2021 | Tags: AbbVie, Rinvoq, upadacitinib, Health Canada, Approval, Atopic Dermatitis Takeda Receives the US FDA Advisory Committee’s Recommendation for TAK-620 (maribavir) to Treat CMV Infection in Post-Transplant Recipients Published: Oct 8, 2021 | Tags: […]Read More

Insights+

Insights+ Key Biosimilars Events of September 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of September, Sandoz entered into a commercialization and license […]Read More

Insights+

PharmaShots’ Key Highlights of Third Quarter 2021

The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular merger agreement to acquired First Wave Bio for ~$229M The key highlights of the big acquisition in this quarter includes Merck acquired Acceleron for ~$11.5B, Baxter acquired Hillrom for ~$10.5B, […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (September 20 – 24, 2021)

Everest’s SPR206 Receives the NMPA’s IND Approval for the Treatment of MDR Gram-Negative Bacterial Infections Published: Sept 24, 2021 | Tags: Everest, SPR206, NMPA, IND, Approval, MDR Gram-Negative Bacterial Infections GE Healthcare to Acquire BK Medical for ~ $1.45B Published: Sept 24, 2021 | Tags: GE Healthcare, Acquire, BK Medical, ~ $1.45B Roche Presents Results […]Read More

Viewpoints

Exclusive Interview with PharmaShots: Ron Elwell of IPM.ai Shares Insight

In an interview with PharmaShots, Ron Elwell, President, and Founder of Swoop and IPM.ai shared his views on the Real Chemistry Clinical Trial Recruitment System that is designed to accelerate clinical investigations and lead to faster patient outcomes with less risk. Shots: Real Chemistry’s IPM.ai accelerates clinical investigation & commercialization of precision medicines leveraging AI […]Read More